GRI Bio (GRI) Liabilities and Shareholders Equity (2020 - 2026)

GRI Bio's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $11.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 180.53% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $30.5 million (up 36.78% YoY), while the FY2025 annual figure was $8.7 million, up 51.0% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $11.3 million, up from $8.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $11.3 million in Q1 2026, with the low at $383000.0 in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $5.6 million (2022), against an average of $5.4 million.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity slumped 95.4% in 2022, then surged 671.8% in 2023.
• GRI Bio's Liabilities and Shareholders Equity stood at $383000.0 in 2022, then soared by 671.8% to $3.0 million in 2023, then soared by 94.15% to $5.7 million in 2024, then soared by 51.0% to $8.7 million in 2025, then jumped by 30.84% to $11.3 million in 2026.
• Business Quant data shows GRI's Liabilities and Shareholders Equity at $11.3 million in Q1 2026, $8.7 million in Q4 2025, and $4.8 million in Q3 2025.